Ibrutinib
Ibrutinib is an inhibitor of Bruton’s tyrosine kinas (BTK), indicated for the treatment of patients with mantle cell lymphoma (MCL).The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1Hpyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one.
Primary Characteristics
It is of Synthetic origin.
It belongs to Protein kinase inhibitor pharmacological group on the basis of mechanism of action.
Molecular Weight: 440.5 · Solubility in Water: insoluble · Non-proprietary name: Ibrutinib.
Pharmacokinetics
Distribution: Ibrutinib has a volume of distribution is 10000L. plasma protein binding is 97.3%.
Elimination: it is metabolised via hepatic, plasma half-life is 4-6hrs, renal excretion is 80% by feces,10% by urine.
Advertisement
Indications
Ibrutinib is primarily indicated in conditions like Mantle Cell Lymphoma.
Contraindications
None recorded.
Dosage
Ibrutinib's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 0 – 560 mg | — | — | PO | recommended dose |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
None recorded.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.8.1 — Immunomodulators